Long-term outcome of bladder augmentation using living-related partial bladder transplantation in rats
Long-term outcome of bladder augmentation using living-related partial bladder transplantation in rats
复制标题
DOI：
10.1203/01.pdr.0000156513.42054.d7
复制
发表时间：
2005-05-01
影响因子：
3.6
通讯作者：
Miyano, T
中科院分区：
文献类型：
--
作者：
Yamataka, A;Wang, K;Miyano, T
比较大鼠活体部分膀胱移植(LPBTx)和传统回肠膀胱成形术(ICP)后膀胱扩大(BA)后的长期组织病理学变化。本研究中，BA(n=37)、LPBTx(n=18)。16周龄Lewis大鼠行心内直视手术(n=19)。5只供体和7只未移植的正常Lewis大鼠(对照组)也进行了研究。BA后10mo存活的大鼠，经血液生化和新膀胱造影术后处死。取膀胱行苏木精-伊红染色和增殖细胞核抗原检测。处死大鼠时，LPBTx组有16只大鼠，ICP组有12只大鼠，ICP大鼠明显小于LPBTx组(p<；0.05)。平均随访时间：LPBTX组为17.3mo，ICP组为13.7mo，供体组为16.1mo，对照组为19.7mo。LPBTx组平均血清pH为7.41+/-0.78，ICP组为7.25+/-0.38。ICP组的平均碱基过剩显著低于LPBTx组(p<；0.05)。LPBTx组的膀胱结石发生率(6.3%)显著低于ICP组(33.3%；p<；0.05)。LPBTx组未见异型增生/恶性/增殖细胞核抗原表达增加。与对照组相比，肝内胆汁淤积症大鼠的增殖细胞核抗原表达增加(p<；0.05)；12只肝内胆汁淤积症大鼠中有2只(16.7%)有异型增生伴有丝分裂。与对照组相比，LPBTx组和ICP组的膀胱容量增加(P<；0.05)。我们希望证明使用LPBTx的BA可以产生比使用ICP的BA更少的并发症；LPBTx也可以降低恶变的风险。
Long-term histopathologic changes after bladder augmentation (BA) in rats using living-related partial bladder transplantation (LPBTx) or conventional ileocystoplasty (ICP) were compared. In this study, BA (n = 37), LPBTx (n = 18). and ICP (n = 19) were performed in 16-wk-old Lewis rats. Five donors and seven nontransplanted normal Lewis rats (controls) were also studied. Rats that survived > 10 mo after BA were killed after blood biochemistry and neobladder imaging. Harvested bladders were examined with hematoxylin and eosin and proliferating cell nuclear antigen (PCNA). When the rats were killed, there were 16 rats in the LPBTx group and 12 rats in the ICP group; ICP rats were significantly smaller than LPBTx rats (p < 0.05). Mean duration of follow-up for the LPBTX group was 17.3 mo, for the ICP group was 13.7 mo, for the donor group was 16.1 mo, and for the control group was 19.7 mo. Mean serum pH in the LPBTx group was 7.41 +/- 0.78 and in the ICP group was 7.25 +/- 0.38. Mean base excess in the ICP group was significantly lower than in the LPBTx group (p < 0.05). Incidence of bladder calculi in the LPBTx group (6.3%) was significantly lower than in the ICP group (33.3%; p < 0.05). There was no dysplasia/malignancy/increase in PCNA in the LPBTx group. PCNA increased in the ICP group, compared with controls (p < 0.05); two (16.7%) of 12 of ICP rats had dysplasia with mitosis. Bladder capacity increased in LPBTx and ICP compared with controls (both p < 0.05). We hope to show that BA using LPBTx may result in a neobladder with fewer complications than BA using ICP; LPBTx may also decrease the risk for malignancy.